

Dr. Shadi Albarqouni



Technical University of Munich (TUM), Faculty of Informatics, CAMPAR, Senior Research Scientist

Shadi Albarqouni is Senior Research Scientist at Chair for Computer Aided Medical Procedures (CAMP) at Technical University of Munich (TUM), Germany.

He received his Ph.D. in Computer Science with summa cum laude in 2017. Since then, he has been working as a postdoctoral researcher at CAMP leading the Medical Image Analysis group with an emphasis on developing deep learning methods for medical applications.

Dr. Albarqouni has more than 30 publications in both Medical Imaging Computing and Computer Assisted Interventions published in IEEE TMI, MICCAI, IPCAI, IJCARS, BMVC, and ICRA. He serves as a reviewer for many journal IEEE TMI, IEEE JBHI, IJCARS and Pattern Recognition. Since 2015, he has been serving as a PC member for a couple of MICCAI workshops.

His current research interests include developing Semi-/Weakly Supervised Deep Learning tackling the medical imaging challenges such as Class Imbalance, Limited amount of labeled data, and domain shift. He is also interested in Entrepreneurship and Startups for Innovative Medical Solutions.

His goal is to help everyone in the world to get better healthcare services with the assistance of informatics and computer science.

Bart de Witte



Futur/io Institute, Hamburg, Chair Faculty of Digital Health; IBM D-A-CH, Director Digital Health

With over 20 years of experience in the digital healthcare industry, Bart de Witte has always been a pioneer of innovation to the healthcare industry. His focus has always been on creating value for the entire value chain, and his goal has always been to make healthcare systems more open & connected, more accessible and more democratic. Whether at SAP or IBM, where he has held executive positions in almost all phases of the software lifecycle, or as a mentor in the creation, development and growth of over a dozen startups in the healthcare market, his focus has always been on integrating cutting-edge technology. He combines experience of the „old“ and „new“ IT business in the healthcare sector. His strength: identifying patterns and trends across multiple systems to simplify complex decision-making. His passion seems to be fueled by his indomitable will to do something for the common good, and to advance the democratization of healthcare driven by technology. He is director of digital health at IBM but has recently been designing, researching and lecturing with the recently founded European Institute for Exponential Technologies and a desirable future, futur.io. In this role, he has launched a Moonshot program focused on the development of Open Sourced AI in medicine, which will be rolled out in early 2019.

Bart de Witte is a regular global keynote speaker and holds degrees from various universities in Belgium and has completed several post-graduate courses at national and international business schools, including Harvard Business School and Fontainebleau INSEAD. He is a faculty member of the University of Applied Sciences Zurich, the University of Applied Sciences Burgenland and founder of the Austrian Quantified Self Organization. Since 2007, he tweets about the news from the digital healthcare sector under the name [@swisshealth20](https://twitter.com/swisshealth20).

**Prof. Dr. Dr. Torsten
Haferlach**



Münchner Leukämielabor GmbH, Founder & CEO

Prof Dr Dr Torsten Haferlach is one of the world's leading experts in the field of leukemia; engaging in ground breaking research, the development of new diagnostic tools as well as the link to treatment options, he has always been pushing its boundaries of his chosen field.

With an MD in medicine as well as a PhD in Germanistics, and a habilitation that already sets standards in the leukemia diagnostic field, he spent the first part of his career as a medical doctor and hematologist, first at the university clinics in Kiel and Göttingen then at the university clinic in Munich where he acted as both the senior physician at the Department of Internal Medicine and the Head of the laboratory for leukaemia diagnostics.

In 2005 he set up the Munich Leukemia Laboratory (www.mll.com) together with three colleagues from complementary disciplines. Today the lab processes with a team of 198 employees over 78,000 blood or bone marrow samples per year, his practice treats more than 4,500 patients, and he is one of the major contributors to knowledge in this area: well over 500 articles have been published in top ranking, peer-reviewed medical journals since the lab's inception.

Prof Haferlach himself has authored and co-authored more than 500 articles over the course of his career. He is constantly contributing to the evaluation and dissemination of scientific knowledge in his chosen field: as reviewer of leading journals including the New England Journal of Medicine, Blood, Leukemia, Haematologica and The Lancet Haematology, as member of editorial boards for journals such as Leukemia, Annals of Hematology, and Leukemia Research, as sought-after speaker on medical conferences around the world, and by serving on the advisory boards of companies such as Illumina, Novartis, Pfizer and Gilead.

Dr. Sabine Hauck



**LEUKOCARE AG, Martinsried, Vice President
Research & Development**

Sabine Hauck is Vice President Research & Development at Munich-based biotech company LEUKOCARE. Within LEUKOCARE's management team she is responsible for the research & development activities of the company.

LEUKOCARE is a specialized formulation development provider in the field of biopharmaceuticals with a strong algorithm-based development approach. Beyond state-of-the-art formulations based on latest textbook development approaches, LEUKOCARE provides a next-generation formulation technology platform providing extra stability resulting in beneficial product features and competitive advantages. LEUKOCARE's SPS® formulation technology platform and formulation services are based on a comprehensive excipient database and, moreover, on an algorithm-based development process. This software-supported design of experiment (DoE) approach helps to avoid/reduce high-throughput screening and strongly increases probability of success. Moreover, it improves stability and quality of biologics like antibodies including high concentration formulations, vaccines including live viral vectors etc. in liquid and dry formulation, and protects proteins in biologically functionalized medical devices like apheresis columns, implants, wound dressings, etc. during sterilization.

Sabine Hauck has nearly 20 years of experience and held various positions in the field of development, quality assurance and regulatory affairs in small to midsize biotech and pharma companies, respectively. Prior to her industry career in drug product development, she was a scientist in biosensor development at Fraunhofer.

Stefanie Peters

Enable2Grow, Berlin, Co-Founder & CEO



Stefanie Peters is co-founder and CEO of enable2grow, the leading consulting firm for digital growth and digital transformation in Europe. With 20 years of experience as strategy consultant with Accenture and BCG and in operational roles with digital startups, she is a versed expert in digital business with a focus on growth topics and has acquired extensive know how and network in the digital community.

With a team of 50+ experienced enablers, senior advisors and topic experts, she advises traditional companies and corporates like ADAC, Jones Lang Lasalle or Deutsche Bahn as well as established digital players like Groupon or Scout24, where she gainfully applies her expertise and international network for growing the digital business of her clients.

Dr. Claudia Schlembach



Hanns-Seidel-Stiftung, München, Akademie für Politik und Zeitgeschehen, Referatsleiterin Wirtschaft und Finanzen

Dr. Claudia Schlembach is Head of the Division Economy and Finance at the Academy for Politics and Current Affairs at the Hanns Seidel Foundation since 2010.

Her portfolio at the Hanns Seidel Foundation covers political advisory, preparing policy papers for decision-makers as well as publications on various topics such as trade policy, game theory, digitalization, the EU's Economic and Monetary Union and the „German Mittelstand“.

Prior to joining the Academy for Politics and Current Affairs, she served as CEO for five years in a consulting firm that advised family businesses. During this time, she established a business unit to train entrepreneurs and start-ups and published several books on family businesses, business plan, the art of selling and negotiating.

With a background in economic and political science, she analyzed strategic planning concepts in her PhD thesis, thereby focusing on game theory and artificial intelligence, and graduated summa cum laude from the University of Munich.

Dr. Howard Urnovitz



Chronix Biomedical, San Jose & Göttingen, Chief Scientific Officer (CSO)

Howard Urnovitz has been researching cancer for over 4 decades. In 1996, Dr. Urnovitz was the first to match genetic material in the blood to the human genome. This diagnostic approach is now referred to as a Liquid Biopsy. Dr. Urnovitz received his PhD from the University of Michigan in 1979 studying how cancers evade the immune system. Now, 40 years later Dr Urnovitz's quest is to use deep learning (DL) to decode the language of the blood by analyzing blood "text messages."

Dr. Urnovitz will trace in his presentation how the introduction of new technologies led to the rise of advancements in genetics and today's revolution in medicine. Much of the medical discoveries are based on the observation that DNA is the blueprint for inheritance. It is the intent of this summary to hypothesize that there is a genome operating system that carries out the functions encoded in DNA. Further, an argument will be made that DL is uniquely poised to be an important technology to unravel the language of cell-to-cell communication by decoding cell-free nucleic acids found in patients with various illnesses.

Dr. Nicola Vona



Ada Health GmbH, Berlin, Director of Reasoning Technology

Dr. Nicola Vona is Director for Reasoning Technology, the AI base of Ada Health, a Berlin-based health and technology company that combines medical knowledge with artificial intelligence to help people better understand and manage their health. Ada Health's goal is to make the future of personalized healthcare accessible to everyone.

The medical knowledge database and AI technology behind Ada have been developed and continuously enhanced by a team of physicians, scientists and software developers over a period of seven years. Since its global launch in 2016, the AI App has been the number one medical app in over 130 countries. To date, more than nine million symptom analyses have been performed with Ada. In addition, the team has entered into various strategic partnerships in recent months, including with Techniker Krankenkasse, the Bill & Melinda Gates Foundation and the Botnar Foundation.

Dr. Vona has worked for Ada Health and its predecessor since 2014. He received his Ph.D. in Theoretical and Mathematical Physics (Magna cum Laude) from the Ludwig-Maximilians-University, Munich.